Abstract 2109P
Background
Vitamin deficiencies and supplement intake is discussed controversially in oncology. Therefore, we aimed to investigate vitamin D, A and E levels and their correlation with clinical characteristics and symptomatic burden in a large pan-cancer cohort.
Methods
25-hydroxy-vitamin D, vitamin A, and vitamin E levels were measured at treatment start in patients receiving palliative cancer treatment at the Medical University of Vienna (MUV) included in the “Biobanking Program for Personalized Immunotherapy” between May 2019 and March 2022. Measurements were performed using a chemiluminescence immunoassay (vitamin D) and high performance liquid chromatography (vitamin A, vitamin E) established at the Department of Laboratory Medicine (MUV). Cut off values defining the normal range were predefined as follows: vitamin D (75-250nmol/L), vitamin A (1.05-2.45μmol/L), vitamin E (12.0-42.0μmol/L). Symptom burden was assessed using the EORTC quality of life questionnaire QLQC-30 and its subscore assessing fatigue.
Results
Vitamin D, A, and E levels were measured in a total of 231 patients (92 females, 139 males, median age: 64 years [range: 23-89]). Median vitamin levels were as follows: vitamin D 66.9nmol/l (range: 10.4-186.0nmol/l), vitamin A 1.64μmol/l (range: 0.29-4.22μmol/l), and vitamin E 35.8μmol/l (range: 20.2-76.8μmol/l). Patients presented with vitamin D deficiencies in 138/231 (59.7%) and vitamin A deficiencies in 34/231 cases (14.7%). No vitamin E deficiencies were detected, however, 25/231 patients (24.2%) presented with vitamin E levels above normal. Vitamin A levels were increased in 26/231 patients (11.3%), while vitamin D levels above the upper limit of normal in 1/231 patient (0.4%). No correlations between vitamin levels and clinical characteristics at sample collection such as sex, age, tumor origin, symptom burden or fatigue were observed (p>0.05). Additionally, no correlation between vitamin levels and overall survival could be detected (p>0.05).
Conclusions
Even though vitamin deficiencies are common in patients with cancer, no influences of vitamin levels on symptom burden, fatigue or survival could be detected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Financial support by the Austrian Federal Ministry for Digital and Economic Affairs, the National Foundation for Research, Technology and Development and the Christian Doppler Research Association.
Disclosure
A.M. Starzer: Financial Interests, Personal, Invited Speaker, Lecture honoraria: AstraZeneca; Financial Interests, Institutional, Research Grant, Industry partner of institutional Christian Doppler Laboratory: Roche; Non-Financial Interests, Member, National Oncology Society: OeGHO; Non-Financial Interests, Member, Oncology society of USA: ASCO; Other, Travel support for conference participation: MSD, Lilly. M. Preusser: Financial Interests, Personal, Advisory Board: Bayer, Bristol Myers Squibb, Novartis, Gerson Lehrman, CMC Contrast, GSK, Mundipharma, Roche, BMJ Journals, MedMedia, AstraZeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dohme, Tocagen, Adastra, Gan & Lee Pharmaceuticals; Financial Interests, Institutional, Research Grant, Clinical Trials and research: Boehringer-Ingelheim, Bristol Myers Squibb, Roche, Daiichi Sankyo, Merck Sharp & Dohme, Novocure, GSK, AbbVie; Financial Interests, Institutional, Coordinating PI: PharmaMar; Non-Financial Interests, Leadership Role, Brain Tumor Group Chair (current): EORTC; Non-Financial Interests, Leadership Role, EANO Past-President (current): EANO; Non-Financial Interests, Other, Member Multi-Site Guideline Advisory Group: ASCO. A.S. Berghoff: Financial Interests, Personal, Invited Speaker: Roche, Bristol Myers Squibb, Merck, AstraZeneca; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: Daiichi Sankyo, Roche. All other authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06